PFA
REPL icon

Pathway Financial Advisers’s Replimune Group REPL Stock Holding History

Pathway Financial Advisers’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$838 – 301
2025
Q3 		$838 Buy
+200
New +$1.28K ﹤0.01% 374

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Pathway Financial Advisers's REPL Position: Q4 2025 in Review

Pathway Financial Advisers sold out of Replimune Group (REPL) in Q4 2025, closing a stake of 200 shares — an estimated $838 sold.

Pathway Financial Advisers first reported a position in REPL in Q3 2025 and held it in 1 quarter. The position peaked at $838 in Q3 2025. 164 funds tracked by Wall St. Rank hold REPL as of Q4 2025.

  • Pathway Financial Advisers reported no remaining Replimune Group position as of Q4 2025 after selling out during the quarter.
  • Pathway Financial Advisers sold 200 Replimune Group shares in Q4 2025, an estimated $838.
  • Pathway Financial Advisers first reported a position in Replimune Group in Q3 2025 and held it in 1 quarter.
  • Pathway Financial Advisers's Replimune Group position peaked at $838 in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Replimune Group as of Q4 2025.

Based on Pathway Financial Advisers's 13F filing for Q4 2025, filed 6 Feb 2026.